Study of the Effect of Elastic Compression (French Class III) on Water Balance Change in Healthy Subjects
NCT ID: NCT02825537
Last Updated: 2016-08-24
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
23 participants
INTERVENTIONAL
2016-07-31
2016-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Design Validation Hemodynamic Study of New Kendall SCD SmartFlow Compression System
NCT05945186
Longitudinal Trial Assessing Cellulite in Women Wearing a New Compression Garment
NCT05959681
A New Intelligent Stocking for Quantification of Edema in the Lower Limbs
NCT05310435
Sweat Sensors for Athletic Performance
NCT03566381
Clinical Evaluation of a Novel Wearable Compression Technology in the Treatment of Lymphedema, An Open-Label Controlled Study
NCT04659564
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
BASIC_SCIENCE
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
With use of compression stocking
Use of compression stocking during 3 consecutives days
Compression stocking
A class III (20 to 36 mm Hg) elastic compression stocking according to the french classification
Without use of compression stocking
No use of compression stocking during 3 consecutives days
No use of compression stocking
No use of compression stocking
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Compression stocking
A class III (20 to 36 mm Hg) elastic compression stocking according to the french classification
No use of compression stocking
No use of compression stocking
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Subject with a Body Mass Index (BMI) between 18.5 and 30 kg/m²,
3. Subject with a body fat percentage between 11 and 27 % of his weight, as measured by impedancemetry,
4. Subject with a muscle mass index of less than 55% of his weight, as measured by impedancemetry,
5. Subject with a water status, as measured by impedancemetry, between + / - 5 liters of his normal value, as indicated by the impedancemetry,
6. Healthy subject, registered in the French biomedical research volunteer national database,
7. Subject whose lower limb measurements correspond to the size grid of the compression stocking used,
8. Subject agreeing to abstain from alcohol intake during all hospitalization periods,
9. Subject practicing under 5 hours of intense physical activity per week, on average, in the 4 weeks preceding the screening visit (marathon training, military training ...),
10. Subject agreeing to abstain from any strenuous activity , especially sports, from the screening visit to the end of study (including during the out-patient period),
11. Subject accepting the constraints of the study,
12. Subject being available during the whole period of the study,
13. Subject who has signed the consent form after being adequately informed and receiving the information sheet,
14. Subject affiliated to the French social security system or receiving benefits of that type.
Exclusion Criteria
2. Subject following a salt-free diet,
3. Subject following or planning to follow a diet,
4. Subject having a temperature ≥ 38,5°C in the morning,
5. Subject having, upon clinical examination, a systolic blood pressure (SBP) \< 91 mmHg or \> 139 mmHg, a diastolic blood pressure (DBP) \< 41 mmHg or \> 89 mmHg, or a heart rate (HR) \< 40 bpm or \> 100 bpm, and judged clinically significant by the investigator,
6. Subject having an intestinal transit disorder that disrupts hydroelectric balance,
7. Alcohol-dependent subject or subject with a positive alcohol breath test,
8. Subject having a localized or general edema (a simple evening edema of the legs or ankles is accepted for inclusion),
9. Subject suffering from insulin-dependent or uncontrolled diabetes (controlled diabetes is accepted),
10. Subject with a serious, stabilized, or progressive illness (as judged by the investigator),
11. Subject with hypertension or heart failure,
12. Subject with known renal function disorders,
13. Subject with known liver failure,
14. Subject with venous insufficiency of clinical class C3, C4, C5 or C6 according to the Clinical / Etiological / Anatomical / Pathophysiological (CEAP) classification,
15. Subject following long-term therapy with diuretics, nonsteroidal anti-inflammatory drugs (NSAIDs), steroids, nutritional supplements or opiates,
16. Subject having, upon questioning or clinical examination, advanced peripheral neuropathy, skin infections, eczematous dermatitis, or weeping skin disorder of the leg,
17. Subject with a medical contraindication to compression therapy according to the interview or clinical examination: phlegmatia coerulea dolens, septic thrombosis, intolerance to the product including the self-supporting band, allergic reaction to any component, arteritis obliterans of lower limbs, advanced diabetic microangiopathy,
18. Subject with active implants, such as a pacemaker or other mechanical heart device , and non-active implants, for example a hip prosthesis (dental implants are authorized),
19. Subject who is participating in another clinical trial or who is in the exclusion period from a previous study,
20. Person deprived of freedom by judicial or administrative decision, or a person hospitalized without their consent,
21. Subject of legal age who is protected by law or under guardianship,
22. Subject with a current mental or psychiatric disorder or a history of mental or psychiatric disorder, or any other factor limiting the collection of informed consent,
23. Person who works for the Contract Research Organisation or for Innothéra laboratories, or has a dependent relationship with these entities.
40 Years
MALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Biotrial
INDUSTRY
Laboratoires Innothera
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Hakim Charfi, MD
Role: PRINCIPAL_INVESTIGATOR
Biotrial
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Biotrial
Rennes, , France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CVE101-15
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.